Keros Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018
Net Income	-160.3	-152.99	-104.68	-58.74	-45.36	-14.14	Upgrade
Depreciation & Amortization	2.29	2.37	1.62	0.9	0.61	0.44	Upgrade
Share-Based Compensation	31.15	28.76	18.68	11.72	4.1	0.06	Upgrade
Other Operating Activities	-7.97	-2.65	14.32	-16.02	3.77	-2.36	Upgrade
Operating Cash Flow	-134.83	-124.51	-70.06	-62.15	-36.89	-16	Upgrade
Capital Expenditures	-2.35	-2.46	-1.24	-1.02	-0.29	-0.27	Upgrade
Investing Cash Flow	-2.35	-2.46	-1.24	-1.02	-0.29	-0.27	Upgrade
Share Issuance / Repurchase	228.43	179.05	120.4	28.55	240.69	0.01	Upgrade
Other Financing Activities	-0.35	-0.09	-0.09	-	55.35	-	Upgrade
Financing Cash Flow	228.08	178.96	120.31	28.55	296.04	0.01	Upgrade
Net Cash Flow	90.9	51.98	49.01	-34.62	258.86	-16.26	Upgrade
Free Cash Flow	-137.18	-126.97	-71.3	-63.17	-37.19	-16.27	Upgrade
Free Cash Flow Margin	-58624.36%	-84087.42%	-	-314.29%	-	-162.69%	Upgrade
Free Cash Flow Per Share	-3.84	-4.31	-2.83	-2.71	-2.40	-6.99	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).